Impact of gag genetic determinants on virological outcome to boosted lopinavir-containing regimen in HIV-2-infected patients

AIDS

Volumn 27, Issue 1, 2013, Pages 69-80

  Larrouy, Lucile ^a   Vivot, Alexandre ^b   Charpentier, Charlotte ^a   Bénard, Antoine ^b,c,d   Visseaux, Benoit ^a   Damond, Florence ^a   Matheron, Sophie ^a   Chene, Geneviève ^b,c,d   Brun Vezinet, Françoise ^a   Descamps, Diane ^a  

^a BICHAT HOSPITAL   (France)

^b BORDEAUX UNIVERSITY HOSPITAL   (France)

^c INSERM   (France)

^d UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

cleavage site; gag; HIV 2; protease inhibitor; resistance

Indexed keywords

DARUNAVIR; GAG PROTEIN; LOPINAVIR; PROTEINASE;

ANTIVIRAL THERAPY; ARTICLE; CLINICAL ARTICLE; EXPLORATORY RESEARCH; FRAMESHIFT MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 2 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IN VIVO STUDY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; VIRUS CAPSID; VIRUS LOAD; VIRUS NUCLEOCAPSID;

DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-2; HUMANS; LOPINAVIR; MALE; MOLECULAR SEQUENCE DATA; MUTATION; POL GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; PROTEASE INHIBITORS; VIRAL LOAD;

EID: 84871621786     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32835a10d8     Document Type: Article

References (59)

1. Guyader M, Emerman M, Sonigo P, Clavel F, Montagnier L, Alizon M. Genome organization and transactivation of the human immunodeficiency virus type 2. Nature 1987; 326: 662-669. (Pubitemid 17059786)
2. Desbois D, Roquebert B, Peytavin G, Damond F, Collin G, Bénard A, et al. In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors. Antimicrob Agents Chemother 2008; 52:1545-1548. (Pubitemid 351522031)
3. Witvrouw M, Pannecouque C, Switzer WM, Folks TM, De Clercq E, Heneine W. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis. Antivir Ther (Lond) 2004; 9:57-65. (Pubitemid 38313948)
4. Tantillo C, Ding J, Jacobo-Molina A, Nanni RG, Boyer PL, Hughes SH, et al. Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance. J Mol Biol 1994; 243:369-387.
5. Dulude D, Baril M, Brakier-Gingras L. Characterization of the frameshift stimulatory signal controlling a programmed-1 ribosomal frameshift in the human immunodeficiency virus type 1. Nucleic Acids Res 2002; 30:5094-5102. (Pubitemid 36033026)
6. Parkin NT, Chamorro M, Varmus HE. Human immunodeficiency virus type 1 gag-pol frameshifting is dependent on downstream mRNA secondary structure: demonstration by expression in vivo. J Virol 1992; 66:5147-5151.
7. Marcheschi RJ, Staple DW, Butcher SE. Programmed ribosomal frameshifting in SIV is induced by a highly structured RNA stem-loop. J Mol Biol 2007; 373:652-663. (Pubitemid 47488399)
8. Brierley I. Ribosomal frameshifting viral RNAs. J Gen Virol 1995; 76 (Pt 8):1885-1892.
9. Felsenstein KM, Goff SP. Expression of the gag-pol fusion protein of Moloney murine leukemia virus without gag protein does not induce virion formation or proteolytic processing. J Virol 1988; 62:2179-2182.
10. Karacostas V, Wolffe EJ, Nagashima K, Gonda MA, Moss B. Overexpression of the HIV-1 gag-pol polyprotein results in intracellular activation of HIV-1 protease and inhibition of assembly and budding of virus-like particles. Virology 1993; 193:661-671.
11. Park J, Morrow CD. Overexpression of the gag-pol precursor from human immunodeficiency virus type 1 proviral genomes results in efficient proteolytic processing in the absence of virion production. J Virol 1991; 65:5111-5117.
12. Damond F, Brun-Vezinet F, Matheron S, Peytavin G, Campa P, Pueyo S, et al. Polymorphism of the human immunodeficiency virus type 2 (HIV-2) protease gene and selection of drug resistance mutations in HIV-2-infected patients treated with protease inhibitors. J Clin Microbiol 2005; 43:484-487. (Pubitemid 40096351)
13. Rodés B, Holguín A, Soriano V, Dourana M, Mansinho K, Antunes F, et al. Emergence of drug resistance mutations in human immunodeficiency virus type 2-infected subjects undergoing antiretroviral therapy. J Clin Microbiol 2000; 38:1370-1374. (Pubitemid 30216656)
14. Rodés B, Sheldon J, Toro C, Jiménez V, Alvarez MA, Soriano V. Susceptibility to protease inhibitors in HIV-2 primary isolates from patients failing antiretroviral therapy. J Antimicrob Chemother 2006; 57:709-713.
15. Colson P, Henry M, Tourres C, Lozachmeur D, Gallais H, Gastaut JA, et al. Polymorphism and drug-selected mutations in the protease gene of human immunodeficiency virus type 2 from patients living in Southern France. J Clin Microbiol 2004; 42:570-577. (Pubitemid 38222630)
16. Pieniazek D, Rayfield M, Hu DJ, Nkengasong JN, Soriano V, Heneine W, et al. HIV-2 protease sequences of subtypes A and B harbor multiple mutations associated with protease inhibitor resistance in HIV-1. AIDS 2004; 18:495-502. (Pubitemid 38365877)
17. Tomasselli AG, Hui JO, Sawyer TK, Staples DJ, Bannow C, Reardon IM, et al. Specificity and inhibition of proteases from human immunodeficiency viruses 1 and 2. J Biol Chem 1990; 265:14675-14683.
18. Brower ET, Bacha UM, Kawasaki Y, Freire E. Inhibition of HIV-2 protease by HIV-1 protease inhibitors in clinical use. Chem Biol Drug Des 2008; 71:298-305. (Pubitemid 351347797)
19. Wu JC, Carr SF, Jarnagin K, Kirsher S, Barnett J, Chow J, et al. Synthetic HIV-2 protease cleaves the GAG precursor of HIV-1 with the same specificity as HIV-1 protease. Arch Biochem Biophys 1990; 277:306-311. (Pubitemid 20098401)
20. Bally F, Martinez R, Peters S, Sudre P, Telenti A. Polymorphism of HIV type 1 gag p7/p1 and p1/p6 cleavage sites: clinical significance and implications for resistance to protease inhibitors. AIDS Res Hum Retroviruses 2000; 16:1209-1213.
21. Gallego O, de Mendoza C, Corral A, Soriano V. Changes in the human immunodeficiency virus p7-p1-p6 gag gene in drugnaive and pretreated patients. J Clin Microbiol 2003; 41:1245-1247. (Pubitemid 36307135)
22. Lambert-Niclot S, Flandre P, Malet I, Canestri A, Soulié C, Tubiana R, et al. Impact of gag mutations on selection of darunavir resistance mutations in HIV-1 protease. J Antimicrob Chemother 2008; 62:905-908.
23. Maguire MF, Guinea R, Griffin P, Macmanus S, Elston RC, Wolfram J, et al. Changes in human immunodeficiency virus type 1 Gag at positions L449 and P453 are linked to I50V protease mutants in vivo and cause reduction of sensitivity to amprenavir and improved viral fitness in vitro. J Virol 2002; 76:7398-7406. (Pubitemid 34760962)
24. Banke S, Lillemark MR, Gerstoft J, Obel N, Jorgensen LB. Positive selection pressure introduces secondary mutations at gag cleavage sites in human immunodeficiency virus type 1 harboring major protease resistance mutations. J Virol 2009; 83:8916-8924.
25. Carrillo A, Stewart KD, Sham HL, Norbeck DW, Kohlbrenner WE, Leonard JM, et al. In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor. J Virol 1998; 72:7532-7541. (Pubitemid 28377885)
26. Garcia-Diaz A, Fox A, Dragsted UB, Kjaer J, Clumeck N, Philips A, et al. Treatment-emergent gag cleavage site mutations during virological failure of ritonavir-boosted protease inhibitors [abstract 73]. In Abstracts of XVII International HIV drug resistance workshop: basic principles and clinical implications; 10 June 2008; Sitges, Spain.
27. Verheyen J, Altmann A, Knops E, Schü lter E, Sichtig N, Reuter S, et al. Relevance of HIV gag cleavage site mutations in failures of protease inhibitor therapies [abstract 48]. In Abstracts of theXVII International HIV drug resistance workshop: basic principles and clinical implications, ; 10 June 2008; Sitges, Spain.
28. Zhang YM, Imamichi H, Imamichi T, Lane HC, Falloon J, Vasudevachari MB, et al. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites. J Virol 1997; 71:6662-6670. (Pubitemid 27355324)
29. Nijhuis M, van Maarseveen NM, Lastere S, Schipper P, Coakley E, Glass B, et al. A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism. PLoS Med 2007; 4:e36.
30. Mammano F, Petit C, Clavel F. Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients. J Virol 1998; 72:7632-7637. (Pubitemid 28377901)
31. Cô té HC, Brumme ZL, Harrigan PR. Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir. J Virol 2001; 75:589-594. (Pubitemid 32037261)
32. Verheyen J, Litau E, Sing T, Däumer M, Balduin M, Oette M, et al. Compensatory mutations at the HIV cleavage sites p7/p1 and p1/p6-gag in therapy-naive and therapy-experienced patients. Antivir Ther (Lond) 2006; 11:879-887. (Pubitemid 44736179)
33. Coren LV, Thomas JA, Chertova E, Sowder RC, Gagliardi TD, Gorelick RJ, et al. Mutational analysis of the C-terminal gag cleavage sites in human immunodeficiency virus type 1. J Virol 2007; 81:10047-10054. (Pubitemid 350067708)
34. Ho SK, Coman RM, Bunger JC, Rose SL, O'Brien P, Munoz I, et al. Drug-associated changes in amino acid residues in Gag p2, p7(NC), and p6(Gag)/p6(Pol) in human immunodeficiency virus type 1 (HIV-1) display a dominant effect on replicative fitness and drug response. Virology 2008; 378:272-281.
35. Kolli M, Schiffer CA. Insights into the mechanism of resistancecoevolution of the nelfinavir-resistant HIV-1 Protease and the p1-p6 cleavage site [abstract 98]. In Abstracts of theXVIII International HIV drug resistance workshop: basic principles and clinical implications; 2009; Fort Meyers, Floride.
36. Verheyen J, Knops E, Kupfer B, Hamouda O, Somogyi S, Schuldenzucker U, et al. Prevalence of C-terminal gag cleavage site mutations in HIV from therapy-näve patients. J Infect 2009; 58:61-67.
37. Fehé r A, Weber IT, Bagossi P, Boross P, Mahalingam B, Louis JM, et al. Effect of sequence polymorphism and drug resistance on two HIV-1 Gag processing sites. Eur J Biochem 2002; 269:4114-4120. (Pubitemid 34994906)
38. Kaufmann GR, Suzuki K, Cunningham P, Mukaide M, Kondo M, Imai M, et al. Impact of HIV type 1 protease, reverse transcriptase, cleavage site, and p6 mutations on the virological response to quadruple therapy with saquinavir, ritonavir, and two nucleoside analogs. AIDS Res Hum Retroviruses 2001; 17:487-497. (Pubitemid 32692331)
39. Kolli M, Stawiski E, Chappey C, Schiffer CA. Human immunodeficiency virus type 1 protease-correlated cleavage site mutations enhance inhibitor resistance. J Virol 2009; 83:11027-11042.
40. Prabu-Jeyabalan M, Nalivaika EA, King NM, Schiffer CA. Structural basis for coevolution of a human immunodeficiency virus type 1 nucleocapsid-p1 cleavage site with a V82A drug-resistant mutation in viral protease. J Virol 2004; 78:12446-12454. (Pubitemid 39458763)
41. Yates PJ, Hazen R, St Clair M, Boone L, Tisdale M, Elston RC. In vitro development of resistance to human immunodeficiency virus protease inhibitor GW640385. Antimicrob Agents Chemother 2006; 50:1092-1095. (Pubitemid 43327819)
42. Doyon L, Croteau G, Thibeault D, Poulin F, Pilote L, Lamarre D. Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors. J Virol 1996; 70:3763-3769. (Pubitemid 26161824)
43. Parry CM, Kohli A, Boinett CJ, Towers GJ, McCormick AL, Pillay D. Gag determinants of fitness and drug susceptibility in protease inhibitor-resistant human immunodeficiency virus type 1. J Virol 2009; 83:9094-9101.
44. Tözsér J, Bláha I, Copeland TD, Wondrak EM, Oroszlan S. Comparison of the HIV-1 and HIV-2 proteinases using oligopeptide substrates representing cleavage sites in Gag and Gag-Pol polyproteins. FEBS Lett 1991; 281:77-80.
45. Chou KC. Prediction of human immunodeficiency virus protease cleavage sites in proteins. Anal Biochem 1996; 233:1-14.
46. Pieniazek D, Ellenberger D, Janini LM, Ramos AC, Nkengasong J, Sassan-Morokro M, et al. Predominance of human immunodeficiency virus type 2 subtype B in Abidjan, Ivory Coast. AIDS Res. Hum Retroviruses 1999; 15:603-608. (Pubitemid 29177857)
47. Kolli M, Lastere S, Schiffer CA. Co-evolution of nelfinavirresistant HIV-1 protease and the p1-p6 substrate. Virology 2006; 347:405-409.
48. Malet I, Roquebert B, Dalban C, Wirden M, Amellal B, Agher R, et al. Association of Gag cleavage sites to protease mutations and to virological response in HIV-1 treated patients. J Infect 2007; 54:367-374. (Pubitemid 46395023)
49. Ghosn J, Delaugerre C, Flandre P, Galimand J, Cohen-Codar I, Raffi F, et al. Polymorphism in Gag gene cleavage sites of HIV-1 Non-B subtype and virological outcome of a first-line lopinavir/ritonavir single drug regimen. PLoS ONE 2011; 6:e24798.
50. Larrouy L, Chazallon C, Landman R, Capitant C, Peytavin G, Collin G, et al. Gag mutations can impact virological response to dual-boosted protease inhibitor combinations in antiretroviral-na?̈ve HIV-infected patients. Antimicrob Agents Chemother 2010; 54:2910-2919.
51. Larrouy L, Lambert-Niclot S, Charpentier C, Fourati S, Visseaux B, Soulié C, et al. Positive impact of HIV-1 gag cleavage site mutations on the virological response to darunavir boosted with ritonavir. Antimicrob Agents Chemother 2011; 55:1754-1757.
52. Dierynck I, De Meyer S, Cao-Van K, Van Marck H, Lathouwers E, Thys K, et al. Impact of gag cleavage site mutations on the virological response to darunavir/ritonavir in treatmentexperienced patients in POWER 1, 2 and 3 [abstract 21]. In Abstracts of theXVI International HIV Drug Resistance Workshop; 12 June 2007; Barbados.
53. Verheyen J, Litau E, Sing T, Schuldenzucker U, Däumer M, Oette M, et al. HIV p7/p1 and p1/p6-gag cleavage site mutations are associated with specific PR mutations and PI resistance profiles [abstract 57]. In Abstracts of the XV International HIV drug resistance workshop: basic principles and clinical implications; 13 June 2006; Sitges, Spain.
54. Parkin N, Chappey C, Lam E, Petropoulos C. Reduced susceptibility to protease inhibitors (PI) in the absence of primary PI resistance-associated mutations [abstract 108]. In Abstracts of the XIV International HIV Drug Resistance Workshop: basic principles and clinical implications; 7 June 2005; Québec City, Québec, Canada.
55. Mammano F, Trouplin V, Zennou V, Clavel F. Retracing the evolutionary pathways of human immunodeficiency virus type 1 resistance to protease inhibitors: virus fitness in the absence and in the presence of drug. J Virol 2000; 74:8524-8531. (Pubitemid 30666703)
56. Callebaut CS, Stray K, Tsai L, Xu L, Lee W, Cihlar T. In Vitro HIV-1 resistance selection to GS-8374, a novel phosphonate protease inhibitor: comparison with lopinavir, atazanavir and darunavir [abstract 16]. In Abstracts of the XVI International HIV Drug Resistance Workshop; 12 June 2007; Barbados
57. Baril M, Dulude D, Gendron K, Lemay G, Brakier-Gingras L. Efficiency of a programmed-1 ribosomal frameshift in the different subtypes of the human immunodeficiency virus type 1 group M. RNA 2003; 9:1246-1253. (Pubitemid 37151678)
58. Telenti A, Martinez R, Munoz M, Bleiber G, Greub G, Sanglard D, et al. Analysis of natural variants of the human immunodeficiency virus type 1 gag-pol frameshift stem-loop structure. J Virol 2002; 76:7868-7873. (Pubitemid 34761010)
59. Knops E, Théberge-Julien G, Kaiser R, Hoffman D, Brakier-Gingras L, Verheyen J. Differences in the frameshift-regulating p1-site in treatment-naive and PI-resistant HIV isolates [abstract 99]. In Abstracts of the XVIII International HIV drug resistance workshop: basic principles and clinical implications; 9 June 2009; Fort Meyers, Floride.